Background: Point mutation of K-ras is associated with carcinogenesis and overall survival in various cancers. We investigated the mutational spectrum of K-ras codon 12 in resected normal and gallbladder cancer tissue samples in a Northern Indian population and correlated it with different clinicopathological parameters. Patients and Methods: Gallbladder tissues from normal (n = 24) and cancer patients (n = 39) were analyzed for K-ras codon 12 mutation by restriction fragment length polymorphism. Statistical analysis was carried out using the χ2 test or Fisher's exact test. Survival was estimated using the Kaplan-Meier method, and the difference between survival curves was analyzed by the log-rank test. Results: The frequency of K-ras mutation was significantly higher (p = 0.001) in gallbladder cancer tissue samples (16/39) compared to normal samples (1/24). Patients with K-ras mutation had a significantly decreased overall survival (p = 0.003), particularly for stage II (p = 0.021) and III (p = 0.009) cancers. No significant correlation was observed with any of the other clinicopathological factors studied. Conclusions: Gallbladder cancer has a high frequency of K-ras codon 12 mutation with poorer outcomes in resected stage II and III disease. K-ras mutational analysis has important prognostic implications that need to be investigated further.

Keywords:
K-ras point mutation, Gallbladder cancer, Overall survival, Prognostic factor
1.
Silk YN, Douglass HO Jr, Nava HR, Driscoll DL, Tartarian G: Carcinoma of the gallbladder: the Roswell Park experience. Ann Surg 1989;210:751-757.
2.
Nevin JE, Moran TJ, Kay S, King R: Carcinoma of the gallbladder: staging, treatment, and prognosis. Cancer 1976;37:141-148.
3.
Perpetuo MD, Valdivieso M, Heilbrun LK, Nelson RS, Connor T, Bodey GP: Natural history study of gallbladder cancer: a review of 36 years experience at M. D. Anderson Hospital and Tumor Institute. Cancer 1978;42:330-335.
4.
Randi G, Franceschi S, La Vecchia C: Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006;118:1591-1602.
5.
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
6.
Cerny WL, Mangold KA, Scarpelli DG: K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992;52:4507-4513.
7.
Kim SW, Her KH, Jang JY, Kim WH, Kim YT, Park YH: K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. J Surg Oncol 2000;75:246-251.
8.
Wistuba II, Gazdar AF: Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004;4:695-706.
9.
Singh MK, Chetri K, Pandey UB, Kapoor VK, Mittal B, Choudhuri G: Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol 2004;19:916-921.
10.
Van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-431.
11.
Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
12.
Chomczynski P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993;15:532-537.
13.
Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G: K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996;77:452-458.
14.
Kapoor VK, McMichael AJ: Gallbladder cancer: an ‘Indian' disease. Natl Med J India 2003;16:209-213.
15.
Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS: Preliminary study of p53 and c-erbB-2 expression in gall bladder cancer in Indian patients. BMC Cancer 2006;6:126.
16.
Dhir V, Mohandas KM: Epidemiology of digestive tract cancers in India IV: gall bladder and pancreas. Indian J Gastroenterol 1999;18:24-28.
17.
Shukla PJ, Barreto SG, Gupta P, Neve R, Ramadwar M, Deodhar K, Mehta S, Shrikhande SV, Mohandas: Is there a role for estrogen and progesterone receptors in gall bladder cancer? HPB (Oxford) 2007;9:285-288.
18.
Varma V, Gupta S, Soin AS, Nundy S: Does the presence of jaundice and/or a lump in a patient with gall bladder cancer mean that the lesion is not resectable? Dig Surg 2009;26:306-311.
19.
Barbacid M: ras genes. Annu Rev Biochem 1997;56:779-827.
20.
Fenoglio-Preiser CM: Selection of appropriate cellular and molecular biologic diagnostic tests in the evaluation of cancer. Cancer 1992:69:1607-1632.
21.
Iwase T, Nakazawa S, Yamao K, Yoshino J, Inui K, Yamachika H, Kanemaki N, Fujimoto M, Okushima K, Miyoshi H, Taki N, Nakamura Y, Mizutani S, Horibe Y, Masui T, Tatematsu M: Ras gene point mutations in gallbladder lesions associated with anomalous connection of pancreatobiliary ducts. Hepatogastroenterology 1997;44:1457-1462.
22.
Watanabe M, Asaka M, Tanaka J, Kurosawa M, Kasai M, Miyazaki T: Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology 1994;107:1147-1153.
23.
Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, Albores-Saavedra J, Gazdar AF: Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995;55:2511-2515.
24.
Tada M, Yokosuka O, Omata M, Ohto M, Isono K: Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer 1990;66:930-935.
25.
Imai M, Hoshi T, Ogawa K: K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis. Cancer 1994;73:2727-2733.
26.
Ajiki T, Fujimori T, Onoyama H, Yamamoto M, Kitazawa S, Maeda S, Saitoh Y: K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 1996;38:426-429.
27.
Hanada K, Tsuchida A, Iwao T, Eguchi N, Sasaki T, Morinaka K, Matsubara K, Kawasaki Y, Yamamoto S, Kajiyama G: Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999;94:1638-1642.
28.
Tanno S, Obara T, Fujii T, Mizukami Y, Shudo R, Nishino N, Ura H, Klein-Szanto AJ, Kohgo Y: Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer 1998;83:267-275.
29.
Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, Shen MC, Deng J, Hsing AW: K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002;8:3156-3163.
30.
Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF: Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer 2011;11:60.
31.
Nagahashi M, Ajioka Y, Lang I, Szentirmay Z, Kasler M, Nakadaira H, Yokoyama N, Watanabe G, Nishikura K, Wakai T, Shirai Y, Hatakeyama K, Yamamoto M: Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary. World J Gastroenterol 2008;14:70-75.
32.
Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-364.
33.
Shrikhande SV, Barreto SG, Singh S, Udwadia TE, Agarwal AK: Cholelithiasis in gallbladder cancer: coincidence, cofactor, or cause! Eur J Surg Oncol 2010;36:514-519.
34.
Wistuba II, Albores-Saavedra J: Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999;6:237-244.
35.
Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN: The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009;133:1600-1606.
36.
Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, Ladanyi M, Riely GJ: Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer 2013;119:356-362.
37.
Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM: Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 1999;59:4919-4926.
38.
Irie A, Anderegg B, Kashani-Sabet M, Ohkawa T, Suzuki T, Halks-Miller M, Curiel DT, Scanlon KJ: Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. Antisense Nucleic Acid Drug Dev 1999;9:341-349.
39.
Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA: Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005;3:413-423.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.